ERBA to feature new urinalysis and diabetes monitoring systems at MEDICA 2014

Nov. 10, 2014

Miami, Florida-based ERBA Diagnostics, Inc., will feature two new fully automated diagnostic testing instruments, the Hb-Vario diabetes monitoring system and the Laura XL urinalysis processer, at MEDICA 2014 in Dusseldorf, Germany, November 12-15. ERBA Diagnostics will also showcase its comprehensive range of testing products, including the Elisa systems for autoimmune and infectious disease, chemistry analyzers, hematology analyzers, urine analyzers, and coagulation systems.

The Hb-Vario is an automated HPLC system that is capable of measuring both glycated hemoglobin (HbA1c) and HbA2 for the monitoring of diabetes. ERBA Diagnostics anticipates launching the product initially in Europe, following CE Mark clearance, followed by a release in select emerging markets.

The benefit of monitoring HbA1c values to better manage diabetes is well documented in numerous studies and is considered a key to reducing co-morbidity complications. According to an industry analyst report cited by ERBA representatives, HbA1c testing is poised to emerge as a popular technology with outpatient clinics and small hospital-based laboratories. The global market for diabetes diagnostics may reach $26 billion next year.

The Laura XL is a fully automated urinalysis and sedimentation processor with the capability to automate urine strip reading as well as performing sedimentation cell analysis for abnormal samples. ERBA Diagnostics will be the exclusive distributor for the product in the United States and Latin America following receipt of regulatory approvals and clearances. The worldwidein vitro diagnostics urinalysis market is estimated to be approximately $600 million per year. Learn more about solutions ERBA Diagnostics offers.

Read more